Rathbones Group’s Summit Therapeutics SMMT Stock Holding History

Rathbones Group’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,317	Closed	-$79.1K	–	638
2023 Q4	$79.1K	Hold	30,317	–	–	﹤0.01%	571
2023 Q3	$56.7K	Buy	+30,317	New	+$57.8K	﹤0.01%	590

Other funds holding SMMT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Rathbones Group's SMMT Position: Q1 2024 in Review

Rathbones Group sold out of Summit Therapeutics (SMMT) in Q1 2024, closing a stake of 30,317 shares — an estimated $79.1K sold.

Rathbones Group first reported a position in SMMT in Q3 2023 and held it in 2 quarters. The position peaked at $79.1K in Q4 2023. 105 funds tracked by Wall St. Rank hold SMMT as of Q1 2024.

Rathbones Group reported no remaining Summit Therapeutics position as of Q1 2024 after selling out during the quarter.
Rathbones Group sold 30,317 Summit Therapeutics shares in Q1 2024, an estimated $79.1K.
Rathbones Group first reported a position in Summit Therapeutics in Q3 2023 and held it in 2 quarters.
Rathbones Group's Summit Therapeutics position peaked at $79.1K in Q4 2023.
105 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2024.

Based on Rathbones Group's 13F filing for Q1 2024, filed 14 May 2024.